drugset / Trial / NCT00679237
Risk Reduction in Coronary Heart Disease
RandomizedParallel-groupOpen-labelPrevention
Summary
Study hypothesis: Multifactorial risk reduction in coronary heart disease can reduce the risk of new coronary heart disease and death
Timeline
- Start
- 2007-09
- Primary completion
- 2019-12
- Completion
- 2019-12
Publications
- Kaldal A, Tonstad S, Jortveit J. Self-reported smoking status and exhaled carbon monoxide in secondary preventive follow-up after coronary heart events: Do our patients tell the truth? Tob Prev Cessat. 2024 Sep 25;10. doi: 10.18332/tpc/191843. eCollection 2024.
- Kaldal A, Tonstad S, Jortveit J. Sex differences in secondary preventive follow-up after coronary heart events. BMC Cardiovasc Disord. 2023 Sep 14;23(1):459. doi: 10.1186/s12872-023-03483-6.
- Kaldal A, Tonstad S, Jortveit J. Association of Troponin T measurements with long-term outcomes in patients with coronary artery disease participating in a secondary prevention trial. BMC Cardiovasc Disord. 2023 Apr 28;23(1):210. doi: 10.1186/s12872-023-03249-0.
- Kaldal A, Tonstad S, Jortveit J. Long-term hospital-based secondary prevention of coronary artery disease: a randomized controlled trial. BMC Cardiovasc Disord. 2021 Dec 16;21(1):600. doi: 10.1186/s12872-021-02426-3.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ezetimibe | Unknown | — | — |
| Comparator | Glimepiride | Small molecule | — | — |
| Comparator | Influenza Virus Vaccine | Vaccine | — | — |
| Comparator | Insulin | Protein / enzyme biologic | — | — |
| Comparator | Metformin | Small molecule | — | — |